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Abstract 36 
Experimental autoimmune myocarditis (EAM) represents a CD4+ T helper (Th) cell-37 
mediated mouse model of inflammatory heart disease. Interferon (IFN)-γ, typically produced 38 
by Th1 cells, reduces EAM severity in myosin heavy-chain-(MyHC)-α peptide/Complete 39 
Freund adjuvant-immunized mice. Thus, developing a vaccination strategy that promotes 40 
differentiation of Th1 cells may be beneficial in EAM.  41 
FMS-like tyrosine kinase 3 Ligand (Flt3L)-induced splenic CD8α+ dendritic cells (DC), 42 
which produce interleukin (IL)-12p35, were identified to selectively induce biased 43 
differentiation towards Th1. Mice vaccinated with MyHC-α-loaded Flt3L-induced splenic 44 
CD8α+ DC were protected from EAM. In contrast, when Flt3L-induced splenic CD8α+ DC 45 
were pre-stimulated and over-activated with LPS and αCD40 antibodies or loaded with 46 
unspecific OVA323-339 peptide instead of MyHC-α peptide, mice developed similar disease 47 
scores as non-vaccinated controls. Vaccination efficacy depended on IFN-γ, since CD8α+-48 
vaccinated IFN-γR-/- mice were not protected. Importantly, splenic CD8α+ vaccination was 49 
independent of regulatory T cells.  50 
Taken together, Flt3L-induced dendritic cell-based antigen-specific vaccination limits 51 
expansion of auto-reactive Th cells and protects mice from autoimmune heart inflammation. 52 
53 
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1.  Introduction 54 
Dilated cardiomyopathy (DCM) represents the most common cause of heart failure in 55 
young patients and often evolves from viral myocarditis [1-3]. Clinical observations suggest 56 
that post-infectious autoimmunity promotes disease development [4, 5]. Experimental 57 
autoimmune myocarditis (EAM) is a mouse model for CD4+ Th cell-mediated post-infectious 58 
myocarditis [6-9] and can be induced in susceptible mouse strains by immunization with 59 
myosin heavy chain (MyHC)-α peptide together with Complete Freund’s adjuvant (CFA) [10, 60 
11]. In wild-type mice, disease severity peaks between 20 and 23 days after immunization.  61 
In the past years, studies have demonstrated that IL-17A accounts for disease 62 
development [6-8], while IFN-γ was considered as a protective cytokine in MyHC-α 63 
peptide/CFA-induced EAM and viral myocarditis [6, 12-17]. Indeed, IFN-γ ligand and IFN-γ 64 
receptor deficient mice were more susceptible to EAM than their wild-type counterparts [14, 65 
15]. Furthermore, mice lacking of the typical Th1 cell T-box transcription factor Tbet showed 66 
increased amounts of IL-17A and consequently higher myocarditis severity than wild-type 67 
mice [6]. Consistently, neutralization of IL-17A by active vaccination or by serial injections of 68 
anti-IL-17A antibodies significantly reduced EAM, but did not confer complete protection [7, 69 
8]. In fact, recent reports showed that IL-17A deficiency per se does not determine myocarditis 70 
severity, but rather protects from development of an inflammatory DCM phenotype [9, 18]. 71 
Nevertheless, IL-17A promotes recruitment of CD11b+ monocytes into the heart of wild-type 72 
mice before the peak of EAM [8, 9]. Other studies suggest that lack of IL-17A can counter-73 
balance and therefore increase the production of protective IFN-γ. [19-21].  74 
On one hand, dendritic cells are potent antigen-presenting cells of the innate immune 75 
system that induce primary T cell responses [22-26] and inflammatory cytokines release [27, 76 
28]. After stimulation with LPS plus αCD40 antibodies, GM-CSF-induced peptide-pulsed bone 77 
marrow-derived dendritic cells (BMDC) (CD8α-CD11c+CD11b+), produce IL-6 and TGF-β 78 
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and induce auto-aggressive CD4+ Th17 cells and autoimmune diseases, such as experimental 79 
autoimmune myocarditis (EAM) [11, 26, 29, 30] and experimental autoimmune uveitis (EAU) 80 
[31].  On the other hand, several subsets of regulatory DC have been described so far. A 81 
specific monocytes-derived subset of nitric oxide- and TNF-α-releasing DC subset, for 82 
example, confines auto-reactive T cell expansion in EAM [32]. Moreover, several lines of 83 
evidence indicate that splenic DC subpopulations of lymphoid origin also modulate T cell 84 
differentiation and promote various cytokine production [33-35]. Indeed, Flt3L-induced splenic 85 
CD8α+CD11c+CD11b- DC have been shown to produce IL-12 and promote differentiation and 86 
expansion of CD4+ Th1 cells [33-36].  87 
Given the protective role of IFN-γ in EAM, we hypothesized that vaccination with 88 
Flt3L-induced self-antigen-loaded splenic CD8α+ DC specifically expands heart-specific CD4+ 89 
Th1 cells, which may protect from cardiac auto-immunity after MyHC-α peptide/CFA-induced 90 
EAM. 91 
92 
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2.  Material and methods 93 
2.1.  Mice 94 
DO11.10, IFN-γR-/-, and CD45.1 mice were previously described [8, 15]. Six- to eight-95 
weeks-old BALB/c male mice were used. All mice were housed in an optimized hygienic area. 96 
Animal experiments were conducted in accordance with the Swiss federal laws and institutional 97 
guidelines. 98 
2.2.  Immunization protocol  99 
Mice were immunized with 150 µg of the MyHC-α (MyHC-α614-634) peptide Ac-100 
SLKLMATLFSTYASAD-OH (Caslo, Denmark) emulsified 1:1 in PBS/CFA (1 mg/ml, 101 
H37Ra; Difco) as described [11]. 102 
2.3.  Histopathology and immunohistochemistry  103 
Myocarditis severity was graded blindly and independently on H&E-stained sections by 104 
two investigators, using grades from 0 to 4 as previously described [26].   105 
2.4.  Isolation of Flt3L-induced splenic CD8α+ dendritic cells  106 
Wild-type mice were daily intra-peritoneally treated for ten days with 10 µg/mouse of 107 
human recombinant FMS-like tyrosine kinase 3 Ligand (Flt3L). After Flt3L treatment, spleens 108 
were digested with Collagenase type IV (Worthington, Lakewood, NJ) and red blood cells were 109 
lysed with ACK. Cell suspensions were stained with the CD8α+ Dendritic Cell Isolation Kit 110 
(Mouse, MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the provider’s 111 
instructions. Stained cells were sorted using an autoMACS Separator (Miltenyi Biotec, 112 
Bergisch Gladbach, Germany), following the provider’s protocol. CD8α+ DC were seeded at a 113 
density of 1.5x106 cells/ml, pulsed with 2 µg/ml MyHC-α-peptide only or pulsed and/or 114 
stimulated with 0.1 µg/ml lipopolysaccharide (LPS) plus 5 µg/ml αCD40 antibodies for 4 115 
hours. After washing, DC were re-suspended in PBS at a density of 2.5x106/ml. Each 116 
 5 
vaccinated syngenic mouse received 0.5 Mio CD8α+ DC by i.v. injection three times, every 117 
second day, as described in Fig. 3A. 118 
2.5.  FACS analysis  119 
Cell suspensions were stained using fluorochrome-conjugated mouse-specific 120 
antibodies as described in detail in the Supplementary data. 121 
2.6.  T cell proliferation assays and ELISA  122 
In vitro co-cultivation of sorted CD4+ T cells (magnetic beads, Miltenyi Biotec, 123 
Bergisch Gladbach, Germany) with CD8α+ DC is described in the Supplementary data. 124 
Cytokines were measured using commercially available ELISA kits (R&D Systems). 125 
2.7.  In vivo CD4+ T cell migration and proliferation  126 
CD4+ T cells (DO11.10 TCR) were first labelled with carboxyfluorescein diacetate 127 
succinimidyl ester (CFSE, Molecular Probes) and then injected intravenously at 1x107 cells per 128 
mouse. Twenty-four hours later, each mouse was i.v. injected with 0.5 Mio of OVA323-339-129 
loaded CD8α+ DC previously stimulated in vitro with LPS (0.1 µg/ml) plus αCD40 antibodies 130 
(0.5 µg/ml) for 4 h, or i.v. injected with 0.5 Mio of untreated OVA323-339-loaded CD8α+ DC. 131 
Forty-eight hours later, axillary lymph nodes (ALN), inguinal lymph nodes (ILN), mediastinal 132 
lymph nodes (MLN), and spleens were collected. Lymph nodes and spleens were digested with 133 
Collagenase type IV and then homogenized prior to cell staining. 134 
2.8.  Statistics  135 
The Mann-Whitney U test was used for the evaluation of severity scores. Normally 136 
distributed data, such as proliferation responses and cytokine levels, were compared using 137 
unpaired, two-tailed Student’s t-test. Statistical analysis was conducted using Prism 4 software 138 
(GraphPad Software). Differences were considered as statistically significant for *p < 0.05. 139 
140 
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3.  Results 141 
3.1.  Phenotype of Flt3L-induced splenic CD8α+ dendritic cells 142 
After showing that CD4+ Th1 cells conferred protection from EAM [8], we used DC 143 
expressing CD8α+ to promote specifically differentiation of IFN-γ-producing CD4+ Th1 cells 144 
[35, 36]. Induction and maturation of CD8α+ DC was performed in vivo by serial injections of 145 
Flt3L in wild-type mice for ten days. CD8α+ DC were sorted from other splenic dendritic cell 146 
populations and analysed by flow cytometry. As shown in Fig. 1A, splenic DC highly 147 
expressed CD8α and CD11c, but low CD11b, indicating their lymphoid origin. Sorted Flt3L-148 
induced CD8α+ DC were left untreated (hereafter referred as to CD8α+) or stimulated in vitro 149 
for 4 h with LPS plus αCD40 antibodies (hereafter referred as to LPS-αCD40/CD8α+) or with 150 
TNF-α (hereafter referred as to TNF/CD8α+). Surface marker phenotype of LPS-151 
αCD40/CD8α+ and TNF/CD8α+ DC displayed elevated levels of the co-stimulatory molecules 152 
CD40, CD80 and CD205, while CD86 and MHC II expression was similar in all groups (Fig. 153 
1B and Suppl. Fig. S1A). Cell-free supernatants were analysed for cytokines using ELISA. 154 
LPS-αCD40/CD8α+ DC produced significantly higher levels of IL-1β and IL-6 than CD8α+ 155 
DC, while TGF-β and IL-23 production was comparable in both groups (Fig. 1C). Flt3-induced 156 
CD8α+ DC were also compared to untreated GM-CSF-induced BMDC, which produced higher 157 
amounts of IL-6, but lower IL-12p35, after analysis by flow cytometry (Suppl. Figs. S1B-S1C). 158 
CD4+ Th cell differentiation has been shown to be also determined by the interaction 159 
between delta-like receptors on DC and Notch ligands on T cells [37, 38]. We observed that 160 
CD8α+ DC expressed high RNA levels of delta-like 1, which promotes CD4+ Th1 cell 161 
differentiation [37], while LPS-αCD40/CD8α+ DC expressed high levels of delta-like 4, which 162 
supports development of CD4+ Th17 cells [38] (Fig. 1D). These data suggest that CD8α+ DC 163 
may specifically promote differentiation of CD4+ Th cell subsets.  164 
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 165 
3.2. CD8α+ and LPS-αCD40/CD8α+ DC have the same potential to prime T cells, but polarise 166 
different CD4+ Th cell subsets  167 
To investigate the potential of CD8α+ DC to prime naïve T cells in vitro, we co-168 
cultivated OVA323-339-peptide-pulsed CD8α+ and LPS-αCD40/CD8α+ DC with titrating 169 
amounts of OVA-specific CD4+ T cells. T cell proliferation assessed by 3H-thymidine 170 
incorporation showed that CD8α+ and LPS-αCD40/CD8α+ DC induced similar proliferation 171 
after 48 and 72 hours of incubation (Fig. 2A). Differentiation of CD4+ Th1 cells is dependent 172 
on Tbet, while the CD4+ Th17 lineage depends on the transcription factor retinoic-acid-173 
receptor-related orphan receptor (ROR)γt [6, 21, 39]. In vitro, CD8α+ DC showed higher Tbet 174 
RNA, but lower RORγt RNA expression, than LPS-αCD40/CD8α+ DC (Fig. 2B-2C). 175 
Consistently, CD8α+ DC produced higher amounts of IFN-γ, but lower amounts of IL-17A, 176 
than LPS-αCD40/CD8α+ DC (Fig. 2B-2C). 177 
To study the priming capacity of CD8α+ DC in vivo, CD45.2 CD8α+ or LPS-178 
αCD40/CD8α+ DC pulsed with OVA323-339-peptide were intravenously injected into CD45.1 179 
wild-type recipient mice 24 hours before transfer of CD45.2 CFSE-labelled DO11.10 (OVA-180 
specific) CD4+ T cells. Migrating CD8α+ and LPS-αCD40/CD8α+ DC, which exerted their 181 
proliferative potential exclusively in mediastinal LN and spleen, showed comparable capacity 182 
to prime CD4+ T cell (Fig. 2D). However, CD8α+ DC promoted proliferation of IFN-γ-183 
producing DO11.10 CD4+ T cells, while LPS-αCD40/CD8α+ DC induced both IFN-γ- and IL-184 
17A-producing DO11.10 CD4+ T cells (Fig. 2D). Taken together, CD8α+ DC support 185 
differentiation of antigen-specific IFN-γ-producing CD4+ Th1 cells, while LPS-CD40/CD8α+ 186 
DC support polarisation of both CD4+ Th1 and IL-17A-producing CD4+ Th17 cells.  187 
 188 
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3.3.  Vaccination with MyHC-α-loaded Flt3L-induced CD8α+ DC prevents EAM 189 
EAM is inducible in BALB/c and A/J mice with a dominant CD4+ Th2 phenotype, 190 
while CD4+ Th1-dominant C57Bl/6 mice are largely resistant [40, 41]. We therefore tested the 191 
potential of CD8α+ DC to promote in vivo a Th1 response in the Th2 dominant BALB/c 192 
background. CD8α+ and LPS-αCD40/CD8α+ DC were pulsed with MyHC-α-peptide for 4 193 
hours. Mice were vaccinated with three intravenous injections of DC at days -7, -5, and -3 194 
before induction of myocarditis with MyHC-α-peptides emulsified in CFA at day 0 and day 7 195 
(Fig. 3A). Negative controls for vaccination were vehicle (PBS) control and vaccination with 196 
three intravenous injections of untreated CD8α+ pulsed with OVA323-339-peptide. As 197 
hypothesized, vaccination with CD8α+ DC protected mice from EAM (Fig. 3B). In contrast, 198 
PBS control and OVA323-339-pulsed CD8α+-vaccinated control mice exhibited severe 199 
myocarditis at day 21, while mice vaccinated with LPS-αCD40/CD8α+ DC had slightly 200 
decreased EAM incidence (Fig. 3B). Myocarditis scores were irrelevant from day 0 to day 21 201 
in mice vaccinated with CD8α+ DC, suggesting that vaccination with CD8α+ DC, in addition to 202 
prevent EAM, was not pathogenic (Figs. 3C-3D). On the other side, vaccination with LPS-203 
αCD40/CD8α+ DC induced mild myocarditis at day 0 and exerted irrelevant protection against 204 
EAM at day 21 when compared to PBS control or OVA323-339-pulsed CD8α+-vaccinated 205 
control mice (Figs. 3C-3D). In addition, treatment with three intravenous injections of GM-206 
CSF-induced BMDC pulsed with MyHC-α-peptide showed even more aggravated disease from 207 
day 0 to day 21 (Fig. 3E). Taken together, these data indicate that only antigen-specific 208 
vaccination with MyHC-α-pulsed CD8α+ DC protects from EAM. 209 
 210 
3.4.  Antigen-specific IFN-γ-producing CD4+ Th1 confer protection from EAM  211 
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CD4+ Th cell differentiation occurs few days after myocarditis induction. At day 2, 212 
sorted splenic CD4+ T cells proliferated to similar extent in all analysed groups, while at day 9, 213 
vaccination with CD8α+ DC inhibited CD4+ T cell proliferation when compared to LPS-214 
αCD40/CD8α+ DC or PBS control vaccination (Fig. 4A). IFN-γ production was observed in 215 
both DC-vaccinated mice, but CD8α+ DC vaccination induced higher levels of IFN-γ than 216 
LPS-αCD40/CD8α+ DC or PBS vaccination. On the other side, IL-17A production was lower 217 
in CD8α+ DC-vaccinated mice than LPS-αCD40/CD8α+ DC-vaccinated mice or PBS only 218 
controls (Fig. 4B). Taken together, CD8α+ DC vaccination promotes protective CD4+ Th1 219 
cells, while LPS-αCD40/CD8α+ DC vaccination induces a mixed CD4+ Th1 and CD4+ Th17 220 
response, which was not protective. 221 
 222 
3.5.  Protection conferred by Flt3L-induced CD8α+ DC depends on IFN-γ 223 
Mice lacking of IFN-γ or IFN-γ receptor (IFN-γR) develop severe EAM scores after 224 
MyHC-α/CFA immunization [13-15], while IFN-γ is critical for a negative feedback loop 225 
confining auto-reactive T cell expansion at the peak of disease [8]. To analyse the role of IFN-γ 226 
in our vaccination strategy, we injected wild-type (IFN-γR+/+) and IFN-γR-/- mice with wild-227 
type CD8α+ DC as described in Fig. 3A. Vehicle (PBS) was used as negative control for 228 
vaccination. Myocarditis severity scores at day 21 indicated that CD8α+ DC vaccination was 229 
efficient in wild-type mice only, but not in IFN-γR-/- mice, while PBS control mice showed 230 
typical EAM development for wild-type and IFN-γR-/- mice [14, 15] (Fig. 5A-5B). Importantly, 231 
CD8α+ DC vaccination in wild-type, but not in IFN-γR-/- mice, significantly reduced MyHC-α-232 
specific CD4+ T cell proliferation (Fig. 5C). These data suggest that IFN-γ is the major 233 
regulator in the protective mechanism conferred by CD8α+ DC vaccination. 234 
 235 
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3.6.  GITR+ regulatory T cells are superfluous in the CD8α+ DC vaccination machinery 236 
Beside CD4+ Th1 cells, regulatory T cells (Tregs) can also produce IFN-γ [42]. Looking 237 
at the typical Tregs differentiation transcription factor FoxP3, we observed that OVA323-339-238 
pulsed CD8α+ and LPS-αCD40/CD8α+ DC co-cultivated in vitro with OVA-specific CD4+ T 239 
cells induced equal expression of FoxP3 RNA (Fig. 6A). In vivo, CD4+FoxP3+GITR+ Tregs 240 
were found in equal amounts in the spleens of CD8α+ DC-, LPS-αCD40/CD8α+ DC-, and PBS 241 
control-vaccinated mice (Fig. 6B). Similarly, IFN-γ produced in CD4+FoxP3+GITR+ Tregs was 242 
comparable in all groups (Fig. 6B). 243 
To test the inhibitory role of Tregs in EAM [43], titrating amounts of GITR+ Tregs 244 
sorted from CD8α+ DC-, LPS-αCD40/CD8α+ DC-, or PBS control-vaccinated mice were co-245 
cultivated in vitro with splenocytes collected from mice with EAM at day 21. As shown in Fig. 246 
6C, GITR+ Tregs sorted from each group were equally efficient in inhibiting proliferation of 247 
MyHC-α-specific splenocytes. These findings indicate that Tregs are not involved in the 248 
protective mechanism induced by CD8α+ DC vaccination.  249 
250 
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4.  Discussion 251 
In this study we propose for the first time a CD8α+ dendritic cell-based vaccination 252 
strategy against MyHC-α/CFA-induced EAM. We managed to specifically expand a protective 253 
MyHC-α-specific CD4+ Th1 response in otherwise Th2-biased BALB/c mice. This protective 254 
CD4+ Th1 response was IFN-γ dependent because our vaccination strategy was not effective in 255 
IFN-γ receptor deficient mice. Importantly, the DC vaccination protocol worked with MyHC-256 
α-loaded non-stimulated Flt3L-inudced CD8α+ DC only, which induced a selective CD4+ Th1 257 
cell response. In contrast, LPS- and αCD40-stimulated Flt3L-induced CD8α+ DC triggered 258 
expansion of mixed Th cell subsets and were not protective at all. 259 
CD4+ Th cell differentiation has been thoroughly studied in the past ten years. From the 260 
first concept of the Th1/Th2 paradigm, new results indicated the presence of another type of 261 
effector Th cells, namely Th17 cells, that produced IL-17A and exhibited effector functions 262 
[44]. Th17 cells are supposed to be potent inducers of tissue inflammation and are associated 263 
with various autoimmune diseases. There is no doubt that IL-17A promotes chronic 264 
inflammation and heart failure in the EAM model, but the specific role of Th17 cells for 265 
induction and early expansion of heart-specific T cell responses is still unclear [9, 18]. In this 266 
study, however, we found that only a selective CD4+ Th1 cell response provides a protective 267 
memory against subsequent MyHC-α/CFA immunization. Accordingly, expansion of a mixed 268 
population of antigen-specific Th1 and Th17 cells observed in LPS-αCD40/CD8α+ DC-269 
vaccinated mice, however, was not protective. We can also not exclude a role for other pro-270 
inflammatory cytokines, such as GM-CSF, in such mixed Th response [45]. Future studies 271 
specifically focused on EAM will be necessary to figure out which pattern of cytokines 272 
produced by Th cells is responsible for EAM induction.  273 
We have previously demonstrated the importance of IFN-γ in the negative feedback 274 
mechanism that confines auto-reactive T cell expansion in EAM [8]. IFN-γ, indeed, initiates the 275 
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final maturation step of heart-infiltrating monocytes to a nitric oxide-releasing anti-276 
inflammatory DC subset, which suppresses activated auto-reactive Th cells [32]. In the present 277 
study, increased IFN-γ production reflected suppressed early T cell expansion and reduced IL-278 
17A levels after vaccination with protective CD8α+ DC. Thus, IFN-γ exerts its protective 279 
effects through different mechanisms at different time-points during the process of early T cell 280 
priming, expansion and disease progression [6, 13, 15]. We believe that rapid in vivo 281 
differentiation towards Th1 cells quickly suppresses pathogenic Th17 cells, which is critical for 282 
disease progression in EAM. In fact, counter-regulation between Th1 and Th17 cells has been 283 
widely described in vitro [19-21, 46]. Nevertheless, here we provide for the first time in vivo 284 
evidence that CD8α+ DC-promoted Th1 differentiation negatively regulates autoimmune 285 
responses. 286 
IFN-γ production is not a prerogative of T cells only. Indeed, DC and Treg also produce 287 
relevant amounts of IFN-γ [42, 47, 48]. However, since IFN-γ production was almost 288 
undetectable in CD8α+ DC, we investigated if regulatory T cells, which produce IFN-γ under 289 
particular stimulatory signals to inhibit Th cells [42], were involved in the induction of 290 
protective IFN-γ. Sorting GITR-expressing Tregs after vaccination [43], however, showed that 291 
the inhibitory potential of Tregs was not affected by our vaccination strategy. All together, the 292 
non-significant production of IFN-γ by CD8α+ DC and Tregs supports our hypothesis that 293 
CD4+ Th1 is indeed the cell population that produces IFN-γ and protects from EAM. 294 
Together with CD8α+ DC, Flt3L also induces proliferation of plasmacytoid DC (pDC) 295 
[34]. We decided to use CD8α+ DC because of their bigger potential to stimulate CD4+ T cells 296 
compared to the very weak stimulatory potential of pDC [49]. Although Flt3L has been 297 
described to worsen autoimmune diseases due to over-expression of stimulatory signals from 298 
pDC, our vaccination strategy starts from serial injections of Flt3L to promote CD8α+ DC in 299 
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vivo, which are then sorted and injected into syngenic mice, facilitating the development of 300 
autologous dendritic cell-based vaccination strategies [50]. 301 
Given the evidence that IL-17A plays a critical role in myocarditis progression and 302 
heart failure development rather than during early auto-reactive T cell priming [9], our 303 
vaccination strategy may be of considerable clinical interest. If it is feasible to selectively bias a 304 
Th1 response in patients during early myocarditis, it may be possible to quench the IL-17A-305 
dependent deleterious late process which leads to end-stage inflammatory cardiomyopathy.  306 
307 
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5.  Conclusions 308 
Here we described for the first time an Flt3L-induced CD8α+ DC-based antigen-309 
specific vaccination strategy which limits auto-reactive T cell expansion and protects mice 310 
from EAM. Moreover, this work contributes to our growing understanding of the role of IFN-γ 311 
in inflammatory heart disease. Our data may be a first step towards a novel ex vivo DC-based 312 
vaccination strategy against inflammatory cardiomyopathy.  313 
 314 
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Figure legends 464 
Fig. 1.  Phenotype of Flt3L-induced splenic CD8α+ dendritic cells.  465 
(A) Purity of sorted splenic dendritic cells checked by analysing expression of the surface 466 
markers CD8α+, CD11c, and CD11b by flow cytometry.  467 
(B) Expression of surface co-stimulatory markers MHCII, CD40, CD80, CD86, and CD205 on 468 
CD8α+ or LPS-αCD40/CD8α+ DC analysed by flow cytometry after 4 h stimulation. 469 
Histograms were gated on CD8α+/CD11c+ DC. The grey area represents isotype control. Mean 470 
fluorescence intensity is shown. 471 
(C) Production of IL-1β, IL-6, IL-23, and TGF-β in CD8α+ (black bars) and LPS-472 
αCD40/CD8α+ (white bars) DC in cell-free supernatants collected after 4 h stimulation 473 
measured by ELISA.  474 
(D) RNA expression of delta-like 4 and delta-like 1 in CD8α+ (black bars) and LPS-475 
αCD40/CD8α+ (white bars) DC after 4 h stimulation measured by qRT-PCR. GAPDH was 476 
used as internal control.  477 
Means ± s.d. Values measured from one out of three independent experiments (A-D) performed 478 
in triplicates (C-D) are shown. *p < 0.05. 479 
 480 
Fig. 2.  CD8α+ DC polarise CD4+ Th1 but not Th17 cells.  481 
(A) OVA323-339-pulsed CD8α+ or LPS-αCD40/CD8α+ DC co-cultivated with titrating amounts 482 
of sorted DO11.10 (OVA-specific) CD4+ T cells. Co-cultures were incubated for 48 h and 72 h. 483 
Proliferation of CD4+ T cells was assessed by 3H-thymidine incorporation.  484 
(B) 105 DO11.10 CD4+ T cells co-cultivated with 104 OVA323-339-pulsed CD8α+ or LPS-485 
αCD40/CD8α+ DC for 48 h. Relative RNA expression of Tbet, IFN-γ, RORγt, and IL-17A with 486 
GAPDH used as internal control is shown. 487 
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(C) IFN-γ and IL-17A were measured in cell-free supernatants collected from co-cultures 488 
described in (B) by ELISA. 489 
(D) CD45.2 OVA323-339-pulsed CD8α+ and LPS-αCD40/CD8α+ DC intravenously injected into 490 
CD45.1 wild-type mice after injection of CFSE-labelled OVA-transgenic CD4+ T cells 491 
(CD45.2). CFSE dilutions corresponding to proliferating DO11.10 transgenic CD4+ T cells 492 
(detected with the KJ1-26 antibody) were measured in axillary lymph nodes (ALN), inguinal 493 
lymph nodes (ILN), mediastinal lymph nodes (MLN) and spleens. All graphs are gated on 494 
CD45.2 positive cells. The right graphs illustrate intracellular FACS analysis for IFN-γ and IL-495 
17A in proliferating OVA-transgenic CD4+ T cells. The percentage of peptide-specific IFN-γ 496 
and IL-17A production refers to proliferating CD45.2+KJ1-26+/CFSE cells.  497 
Means ± s.d. Values measured from one out of three independent experiments performed in 498 
triplicates (A-C), or one out of two representative experiments (D) are shown. *p < 0.05. 499 
 500 
Fig. 3. Vaccination with CD8α+ DC prevents EAM.  501 
(A) Graphic representation of the strategy used to vaccinate mice with CD8α+ DC before 502 
myocarditis induction. 503 
(B) Myocarditis score disease at day 21 evaluated according to the criteria described in the 504 
Methods section. Each symbol represents disease severity of individual mice, bars are groups 505 
means. **p = 0.0086 for CD8α+ DC vs. LPS-αCD40/CD8α+ DC, **p = 0.0045 for CD8α+ DC 506 
vs. PBS control, **p = 0.0045 for CD8α+ DC vs. OVA323-339-loaded CD8α+ DC. 507 
(C) Time course of EAM in vaccinated mice. Vaccination with CD8α+ DC, LPS-508 
αCD40/CD8α+ DC, PBS control, or OVA323-339-loaded CD8α+ DC was performed before 509 
induction of myocarditis. Each time-point represents the mean score disease of four mice.  510 
(D) Haematoxylin and eosin staining of heart cross-sections collected at day 21. 20X and 200X 511 
magnifications are shown. 512 
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(E) Time course of EAM in mice injected with GM-CSF-induced BMDC before induction of 513 
myocarditis. Each time-point represents the mean score disease of four mice. 514 
 515 
Fig. 4. CD8α+ DC exclusively polarise CD4+ Th1 cells, while LPS-αCD40/CD8α+ DC induce 516 
both CD4+ Th1 and CD4+ Th17 cells.  517 
(A) Splenic CD4+ T cells sorted at the indicated days from CD8α+ DC-, LPS-αCD40/CD8α+ 518 
DC-, or PBS control-vaccinated mice were co-cultivated on irradiated (25 Gy) MyHC-α-pulsed 519 
or un-pulsed CD4- wild-type splenocytes for 48 h. Peptide specific proliferation was assessed 520 
calculating the difference between peptide-pulsed CD4+ T cells and un-pulsed CD4+ T cells (∆ 521 
cpm). *p < 0.05 for CD8α+ DC vs. LPS-αCD40/CD8α+ DC and for CD8α+ DC vs. PBS 522 
control. 523 
 (B) IFN-γ and IL-17A were measured after 48 h in the supernatants of the same co-cultures 524 
described in (A). IFN-γ and IL-17A concentrations quantified by ELISA are represented as the 525 
difference between cytokines produced by MyHC-α-pulsed CD4+ T cells and un-pulsed CD4+ 526 
T cells. *p < 0.05. 527 
Means ± s.d. Values from 5 culture wells of one out of three representative experiments (A-B) 528 
are shown.  529 
 530 
Fig. 5. IFN-γ regulates the protective mechanism conferred by CD8α+ DC vaccination.  531 
(A) Myocarditis was induced in wild-type and IFN-γR-/- mice vaccinated with wild-type CD8α+ 532 
DC or PBS control as shown in Fig. 3A. Haematoxylin and eosin staining of heart cross-533 
sections collected at day 21 are shown at magnifications of 20X and 200X.  534 
(B) Myocarditis score disease at day 21 evaluated according to the criteria described in the 535 
Methods section. Each symbol represents disease severity of individual mice, bars are groups 536 
means. *p = 0.0109 for wild-type mice vaccinated with CD8α+ vs. wild-type mice with PBS 537 
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control vaccination, ***p = 0.0002 for wild-type mice vaccinated with CD8α+ vs. IFN-γR-/- 538 
mice vaccinated with CD8α+, n.s. (not significant) p = 0.8808 for IFN-γR-/- mice vaccinated 539 
with CD8α+ vs. IFN-γR-/- mice with PBS control vaccination. 540 
(C) Splenic CD4+ T cells sorted from the same vaccinated mice described in (A) were re-541 
stimulated for 48 h on irradiated MyHC-α-pulsed or un-pulsed antigen presenting cells in the 542 
presence of 2 µg/ml MyHC-α-peptide. Splenocytes proliferation was assessed by 3H-thymidine 543 
incorporation in triplicates. The difference between peptide-specific and peptide-unspecific 544 
proliferating cells (∆ cpm) is indicated. Mean ± s.d. values of ∆ cpm from 5 individual mice are 545 
shown. *p < 0.05. 546 
 547 
Fig. 6. CD4+FoxP3+GITR+ regulatory T cells are not involved in vaccination protection.  548 
(A) 105 DO11.10 CD4+ T cells co-cultivated with 104 OVA323-339-pulsed CD8α+ or LPS-549 
αCD40/CD8α+ DC for 48 h. Relative RNA expression of FoxP3 with GAPDH used as internal 550 
control is shown. 551 
(B) Regulatory T cell analysis after vaccination with CD8α+ DC, LPS-αCD40/CD8α+ DC, or 552 
PBS control at day 0. Splenocytes were stained for surface markers with CD4, GITR, and for 553 
intracellular markers with FoxP3. Tregs depicted on the left graphs are gated on CD4+ cells, 554 
while IFN-γ production was assessed gating on CD4+FoxP3+GITR+ cells.  555 
(C) Titrating amounts of GITR+ regulatory T cells sorted from mice vaccinated with CD8α+ 556 
DC (black circles), LPS-αCD40/CD8α+ DC (white diamonds), or PBS control (silver triangles) 557 
were in vitro co-cultivated for 48 h with MyHC-α-restimulated splenocytes sorted from mice 558 
with myocarditis in the presence of 2 µg/ml MyHC-α-peptide. Proliferating splenocytes control  559 
(grey squares) were cultivated in the absence of Tregs. Splenocytes proliferation was assessed 560 
by 3H-thymidine incorporation in triplicates. 561 
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One out of three representative experiments (A-C) is shown. 562 
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